Pdt Partners, LLC Altimmune, Inc. Transaction History

Pdt Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $419,875 - $881,855	-39,351 Reduced 69.94%	16,915 $216,000
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $268,357 - $801,666	-68,111 Reduced 54.76%	56,266 $658,000
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $32,455 - $51,984	5,501 Added 4.63%	124,377 $757,000
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $1.03 Million - $1.48 Million	118,876 New	118,876 $1.09 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.